Spondyloarthritis & psoriatic arthritis
Dual impact of interleukin-17 A blockade on inflammatory and stromal pathways in peripheral spondyloarthritis
Authors' conclusion
Our findings provide new insights into the molecular mechanisms of IL-17 A blockade in pSpA, underscoring its unique role in selectively targeting bone-remodeling processes specific to the joints of individuals with SpA.
Study context
- Population
- Patients with peripheral SpA (pSpA) (incl. Psoriatic arthritis (PsA)) treated with IL-17Ai
- Participants
- 12 / 7 / 15 / 7
- Comparison
- Synovial tissue before vs after 12 weeks of IL-17Ai; IL-17Ai synovial response in PsA compared with IL-17Ai skin response in psoriasis and with IL-12p40/IL-23p40 blockade in PsA synovium
- pSpA IL-17Ain = 12
- PsA IL-17Ain = 7
- Psoriasis (PsO) IL-17Ain = 15
- PsA IL-12p40/IL-23p40 blockaden = 7
- Outcome
- Synovial gene expression vs baseline
- Follow-up
- Week 12
Methodological detailssynovial biopsies before and after 12 weeks of treatment, RNA-sequencing and qPCR, comparison with open-source skin gene expression data
- Synovial biopsies before and after 12 weeks of treatment
- RNA-sequencing and qPCR
- Comparison with open-source skin gene expression data
Main finding
As reported in the abstract
Genes significantly modulated by IL-17Ai (FDR < 0.1)
1255
Upregulated genes
549
Downregulated genes
706
Original publication
Dual impact of interleukin-17 A blockade on inflammatory and stromal pathways in peripheral spondyloarthritis. Arthritis Res Ther. Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →